Cresco Labs (TSE:CL) has released an update.
Cresco Labs Inc. announced robust financial results for Q2 2024, showcasing a significant year-over-year surge in Adjusted EBITDA Margin and maintaining leading market positions in several states. The company reported a 33% increase in Adjusted EBITDA, achieved $184 million in revenue, and demonstrated strong operational performance through their Sunnyside dispensaries, despite a one-time loss due to a recent tax position adjustment.
For further insights into TSE:CL stock, check out TipRanks’ Stock Analysis page.
